MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to shrink spleen and ease symptoms in hard-to-treat bone marrow cancer
Disease control Not yet recruitingThis early-phase study tests an oral drug called PMD-026 in 18 adults with myelofibrosis, a rare bone marrow disorder. The drug targets a protein (RSK1) to reduce spleen swelling and improve symptoms. Participants must have already tried a JAK inhibitor without success. The main …
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 05:29 UTC
-
New hope for myelofibrosis patients: experimental drug targets enlarged spleen
Disease control Not yet recruitingThis study tests an experimental drug called TQ05105 in about 51 adults with intermediate or high-risk myelofibrosis, a rare bone marrow disorder. The drug is given to people whose disease has not responded to or has come back after standard JAK inhibitor therapy. The main goal i…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 05:28 UTC
-
New hope for myelofibrosis: drug combo targets spleen swelling without prior JAK treatment
Disease control Not yet recruitingThis study tests a combination of two drugs, pacritinib and selinexor, in people with myelofibrosis who have not taken JAK inhibitors before and have low red blood cell and platelet counts. The goal is to see if the combination can shrink an enlarged spleen and improve symptoms. …
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated May 17, 2026 05:27 UTC
-
New drug combo aims to shrink enlarged spleens in hard-to-treat blood cancer
Disease control Not yet recruitingThis study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a rare bone marrow cancer. It includes 40 adults who either did not improve enough on momelotinib alone or had low blood counts. The main goal is to see if the combina…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: United Lincolnshire Hospitals NHS Trust • Aim: Disease control
Last updated May 17, 2026 05:27 UTC
-
New hope for tough blood cancers: experimental drug rebecsinib enters early trial
Disease control Not yet recruitingThis early-phase study tests a new drug called rebecsinib in 28 people with two types of blood cancer: secondary acute myeloid leukemia (sAML) that has come back or not responded to treatment, or higher-risk myelofibrosis (MF). The goal is to find the safest and most effective do…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Aspera Biomedicines, Inc. • Aim: Disease control
Last updated May 17, 2026 05:08 UTC
-
New combo therapy aims to tame bone marrow cancer
Disease control Not yet recruitingThis early-phase study tests whether adding the drug ropeginterferon alfa-2b to the standard treatment ruxolitinib is safe for people with myelofibrosis, a type of bone marrow cancer. About 15 adults who are already on a stable dose of ruxolitinib will receive the combination. Th…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Which drug wins for myelofibrosis? new trial pits momelotinib against ruxolitinib
Disease control Not yet recruitingThis study tests two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug is better at shrinking the spleen and reducing the need for blood transfusions. About 268 participants will b…
Matched conditions: MYELOFIBROSIS
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 15, 2026 11:54 UTC